Volume Alert - BSX 13.50 Boston Scientific Corp $BSX Hit a high today of 13.55 Closing the day 10:29 at 13.50 +0.09 +0.67% With a day low of 13.44 and a total volume of 1,924,117.
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
Insider Trading Alert - UIS, BSX And OLED Traded By Insiders
at The Street - 1 hr 1 min ago
Stocks with insider trader activity include UIS, BSX and OLED
BSX: 13.39 (-0.02), OLED: 27.69 (+0.23), UIS: 27.32 (-0.58)
Pegasus Legal Funding Foresees an Increase in Transvaginal Mesh Lawsuits Following Spotlight on Recent $73MM Jury Award
PR Newswire - Thu Nov 13, 6:34AM CST
Pegasus Legal Funding, LLC, announced today that they plan to prioritize their pre-settlement funding claims on transvaginal mesh cases based on the recent upswing in lawsuits being filed against Boston Scientific Corp. and others. Earlier this month Bloomberg News announced that a $73 million verdict was awarded to a Texas plaintiff in a transvaginal mesh lawsuit filed against Boston Scientific, however, that award has since been cut to $11 million due to the fact that Texas caps punitive damages at no more than two times a plaintiff's economic losses, plus up to $750,000 in non-economic losses.
BSX: 13.39 (-0.02)
Neurostimulation Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario And Forecasts, 2012 To 2020
M2 - Thu Nov 13, 2:52AM CST
Industry Insights
BSX: 13.39 (-0.02), MDT: 69.29 (+0.79), CYBX: 50.97 (+0.45)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.39 (-0.02), VIVO: 16.56 (-0.32), ABAX: 55.18 (+0.98), OSUR: 8.99 (-0.19)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 13.39 (-0.02), MMSI: 15.13 (-0.27)
Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), OMCL: 32.66 (+0.75)
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), BCR: 165.92 (+0.71), ABAX: 55.18 (+0.98)
Nevro - I Remain Cautious After A Successful Debut For This Pain Relief Company
The Value Investor - at Seeking Alpha - Tue Nov 11, 7:43AM CST
BSX: 13.39 (-0.02), NVRO: 25.22 (+0.12)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.39 (-0.02), ABT: 44.49 (+0.26), MDT: 69.29 (+0.79), CSII: 29.50 (-0.12), LMAT: 7.15 (+0.01)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), WAG: 67.10 (-0.34)
Medtronic launches MRI-compatible ICD system in Japan
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:49AM CST
BSX: 13.39 (-0.02), MDT: 69.29 (+0.79), STJ: 65.64 (-0.04)
Could This Obamacare Tax Be Repealed?
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 09, 7:18AM CST
Source: White House on Flickr. With the midterm elections now in the rear-view mirror, Americans can begin speculating about the policies that will come out of Washington over the next two years. Personally, I can't say I'm a huge fan of the...
ZMH: 110.77 (-0.10), BSX: 13.39 (-0.02), MDT: 69.29 (+0.79), NUVA: 43.27 (-0.48)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), BIOS: 5.79 (+0.02)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.39 (-0.02)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), OMCL: 32.66 (+0.75)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.39 (-0.02), WMGI: 28.59 (+0.39), GWPH: 75.36 (+0.04), ABAX: 55.18 (+0.98)
2 Health Care Stocks to Watch on GOP Congressional Takeover - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 06, 4:02PM CST
These health care stocks could benefit if Republicans push for changes in the medical sector.
BSX: 13.39 (-0.02), SYK: 88.63 (+0.05), HUM: 138.71 (+1.46)
Technical Coverage on Health Care Equipment Stocks - Boston Scientific, Zeltiq Aesthetics, Globus Medical, Volcano, and Stryker
PR Newswire - Thu Nov 06, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Volcano Corporation (NASDAQ: VOLC), and Stryker Corporation (NYSE: SYK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, November 5, 2014, the NASDAQ Composite ended at 4,620.72, down 0.06%, the Dow Jones Industrial Average advanced 0.58%, to finish the day at 17,484.53, and the S&P 500 closed at 2,023.57, up 0.57%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, while the index has advanced 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
BSX: 13.39 (-0.02), ZLTQ: 27.01 (-0.39), GMED: 23.04 (-0.12), VOLC: 10.96 (-0.11), SYK: 88.63 (+0.05)
GOP Win Lifts TransCanada, Medical Device, Coal Stocks
at Investor's Business Daily - Wed Nov 05, 1:35PM CST
Prospects for approval of the Keystone XL pipeline, and for Calgary-based pipeline operator TransCanada (TRP), brightened after the GOP gained control of the Senate Tuesday. The power shift in Washington is also expected to benefit medical device...
BSX: 13.39 (-0.02), BTU: 11.08 (-0.52), MDT: 69.30 (+0.80), TRP: 49.82 (-0.54), STJ: 65.65 (-0.03), ANR: 2.41 (-0.21)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.39 (-0.02), CRUS: 19.00 (-0.56), LLY: 67.80 (+0.40)
BSX Recent Posts: http://investorshangout.com/Boston-Scientific...BSX-50374/
BSX Boston Scientific Corp Recent Headline News
Insider Trading Alert - UIS, BSX And OLED Traded By Insiders
at The Street - 1 hr 1 min ago
Stocks with insider trader activity include UIS, BSX and OLED
BSX: 13.39 (-0.02), OLED: 27.69 (+0.23), UIS: 27.32 (-0.58)
Pegasus Legal Funding Foresees an Increase in Transvaginal Mesh Lawsuits Following Spotlight on Recent $73MM Jury Award
PR Newswire - Thu Nov 13, 6:34AM CST
Pegasus Legal Funding, LLC, announced today that they plan to prioritize their pre-settlement funding claims on transvaginal mesh cases based on the recent upswing in lawsuits being filed against Boston Scientific Corp. and others. Earlier this month Bloomberg News announced that a $73 million verdict was awarded to a Texas plaintiff in a transvaginal mesh lawsuit filed against Boston Scientific, however, that award has since been cut to $11 million due to the fact that Texas caps punitive damages at no more than two times a plaintiff's economic losses, plus up to $750,000 in non-economic losses.
BSX: 13.39 (-0.02)
Neurostimulation Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario And Forecasts, 2012 To 2020
M2 - Thu Nov 13, 2:52AM CST
Industry Insights
BSX: 13.39 (-0.02), MDT: 69.29 (+0.79), CYBX: 50.97 (+0.45)
Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.39 (-0.02), VIVO: 16.56 (-0.32), ABAX: 55.18 (+0.98), OSUR: 8.99 (-0.19)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 13.39 (-0.02), MMSI: 15.13 (-0.27)
Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), OMCL: 32.66 (+0.75)
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:50PM CST
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), BCR: 165.92 (+0.71), ABAX: 55.18 (+0.98)
Nevro - I Remain Cautious After A Successful Debut For This Pain Relief Company
The Value Investor - at Seeking Alpha - Tue Nov 11, 7:43AM CST
BSX: 13.39 (-0.02), NVRO: 25.22 (+0.12)
U.S. Market for Peripheral Vascular Devices and Accessories Executive Summary: By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion
M2 - Tue Nov 11, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rwwd3/u_s_market_for) has announced the addition of the "U.S. Market for Peripheral Vascular Devices and Accessories (Executive Summary)" report to their offering. The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period. Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval. Scope - Competitor Analysis - Identified Strategic Opportunities - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Main Segments Included: - Peripheral Vascular Stent Market - PTA Balloon Catheter Market - Atherectomy Device Market - Chronic Total Occlusion (CTO) Device Market - Embolic Protection Device Market - Stent Graft Market - Surgical Graft Market - AV Access Thrombectomy Device Market - Inferior Vena Cava Filter Market - Diagnostic and Interventional Catheter Market - Diagnostic and Interventional Guidewire Market - Introducer Sheath Market - Vascular Closure Device Market - Transcatheter Embolization Device Market Companies Mentioned - ALN International Inc. - Abbott Laboratories - AccessClosure - AngioDynamics - AngioScore - Angiotech - Argon Medical - Arstasis - Artegraft - Asahi Intecc USA - Atrax - Atrium Medical - B. Braun - Boston Scientific - C. R. Bard - Cardiovascular Systems Inc - Cardiva CeloNova Biosciences - Cook Medical - Cordis - Covidien - Endologix - IDEV Technologies - LeMaitre Vascular - MEDRAD - Maquet - Marine Polymer Technologies - Medtronic - Morris Innovative - Penumbra - Pfizer For more information visit http://www.researchandmarkets.com/research/3r...market_for About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BSX: 13.39 (-0.02), ABT: 44.49 (+0.26), MDT: 69.29 (+0.79), CSII: 29.50 (-0.12), LMAT: 7.15 (+0.01)
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:30PM CST
The controversy surrounding an inflated fiscal 2016 earnings forecast continues for leading drugstore chain Walgreen Co. (WAG).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), WAG: 67.10 (-0.34)
Medtronic launches MRI-compatible ICD system in Japan
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 9:49AM CST
BSX: 13.39 (-0.02), MDT: 69.29 (+0.79), STJ: 65.64 (-0.04)
Could This Obamacare Tax Be Repealed?
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 09, 7:18AM CST
Source: White House on Flickr. With the midterm elections now in the rear-view mirror, Americans can begin speculating about the policies that will come out of Washington over the next two years. Personally, I can't say I'm a huge fan of the...
ZMH: 110.77 (-0.10), BSX: 13.39 (-0.02), MDT: 69.29 (+0.79), NUVA: 43.27 (-0.48)
BioScrip (BIOS) Q3 Loss Wider than Expected, Revenues Top - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:10PM CST
BioScrip, Inc. (BIOS) recently declared its third-quarter 2014 results.
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), BIOS: 5.79 (+0.02)
Boston Scientific (BSX) Breaks Through Support at $13.31
Comtex SmarTrend(R) - Fri Nov 07, 12:25PM CST
Boston Scientific (NYSE:BSX) has opened bearishly below the pivot of $13.37 today and has reached the first level of support at $13.31. Analysts will be watching for a cross of the next downside pivot targets of $13.27 and $13.17.
BSX: 13.39 (-0.02)
Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 13.39 (-0.02), ICUI: 84.05 (-0.68), ABAX: 55.18 (+0.98), OMCL: 32.66 (+0.75)
Wright Medical Posts Wider Q3 Loss; Lowers '14 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:50AM CST
Following the earnings release, shares of Wright Medical Group Inc. (WMGI) dropped nearly 5.7% to close at $28.44 yesterday.
BSX: 13.39 (-0.02), WMGI: 28.59 (+0.39), GWPH: 75.36 (+0.04), ABAX: 55.18 (+0.98)
2 Health Care Stocks to Watch on GOP Congressional Takeover - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 06, 4:02PM CST
These health care stocks could benefit if Republicans push for changes in the medical sector.
BSX: 13.39 (-0.02), SYK: 88.63 (+0.05), HUM: 138.71 (+1.46)
Technical Coverage on Health Care Equipment Stocks - Boston Scientific, Zeltiq Aesthetics, Globus Medical, Volcano, and Stryker
PR Newswire - Thu Nov 06, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Boston Scientific Corporation (NYSE: BSX), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), Globus Medical Inc. (NYSE: GMED), Volcano Corporation (NASDAQ: VOLC), and Stryker Corporation (NYSE: SYK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, November 5, 2014, the NASDAQ Composite ended at 4,620.72, down 0.06%, the Dow Jones Industrial Average advanced 0.58%, to finish the day at 17,484.53, and the S&P 500 closed at 2,023.57, up 0.57%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, while the index has advanced 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
BSX: 13.39 (-0.02), ZLTQ: 27.01 (-0.39), GMED: 23.04 (-0.12), VOLC: 10.96 (-0.11), SYK: 88.63 (+0.05)
GOP Win Lifts TransCanada, Medical Device, Coal Stocks
at Investor's Business Daily - Wed Nov 05, 1:35PM CST
Prospects for approval of the Keystone XL pipeline, and for Calgary-based pipeline operator TransCanada (TRP), brightened after the GOP gained control of the Senate Tuesday. The power shift in Washington is also expected to benefit medical device...
BSX: 13.39 (-0.02), BTU: 11.08 (-0.52), MDT: 69.30 (+0.80), TRP: 49.82 (-0.54), STJ: 65.65 (-0.03), ANR: 2.41 (-0.21)
Insider Trading Alert - LLY, CRUS And BSX Traded By Insiders
at The Street - Wed Nov 05, 10:24AM CST
Stocks with insider trader activity include LLY, CRUS and BSX
BSX: 13.39 (-0.02), CRUS: 19.00 (-0.56), LLY: 67.80 (+0.40)
